Price T Rowe Associates Inc Fate Therapeutics Inc Transaction History

Price T Rowe Associates Inc

$869 Billion
Q3 2024

A detailed history of Price T Rowe Associates Inc transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 65,219 shares of FATE stock, worth $109,567. This represents 0.0% of its overall portfolio holdings.

Number of Shares

65,219

Previous 65,219 -0.0%

Holding current value

$109,567

Previous $214,000 7.01%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$3.26 - $7.08 $681,568 - $1.48 Million	-209,070 Reduced 76.22%	65,219 $214,000
Q1 2024 May 15, 2024	BUY	$3.54 - $8.35 $778,559 - $1.84 Million	219,932 Added 404.61%	274,289 $2.01 Million
Q4 2023 Feb 14, 2024	SELL	$1.65 - $3.94 $1.52 Million - $3.64 Million	-923,505 Reduced 94.44%	54,357 $204,000
Q3 2023 Nov 14, 2023	BUY	$2.02 - $5.04 $31,722 - $79,148	15,704 Added 1.63%	977,862 $2.07 Million
Q2 2023 Aug 14, 2023	SELL	$4.76 - $6.59 $2.56 Million - $3.54 Million	-537,874 Reduced 35.86%	962,158 $4.58 Million
Q1 2023 May 15, 2023	SELL	$4.24 - $11.12 $4.91 Million - $12.9 Million	-1,159,026 Reduced 43.59%	1,500,032 $8.55 Million
Q4 2022 Feb 14, 2023	SELL	$9.86 - $23.83 $4.76 Million - $11.5 Million	-482,595 Reduced 15.36%	2,659,058 $26.8 Million
Q3 2022 Nov 14, 2022	SELL	$21.04 - $36.06 $38.8 Million - $66.4 Million	-1,841,850 Reduced 36.96%	3,141,653 $70.4 Million
Q2 2022 Aug 15, 2022	BUY	$17.78 - $42.39 $1.28 Million - $3.06 Million	72,136 Added 1.47%	4,983,503 $123 Million
Q1 2022 May 16, 2022	BUY	$29.67 - $60.28 $29 Million - $58.9 Million	977,429 Added 24.85%	4,911,367 $190 Million
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $1.08 Million - $1.45 Million	-22,557 Reduced 0.57%	3,933,938 $230 Million
Q3 2021 Nov 15, 2021	BUY	$59.27 - $95.73 $50.2 Million - $81.1 Million	846,663 Added 27.23%	3,956,495 $235 Million
Q2 2021 Aug 16, 2021	SELL	$67.25 - $92.52 $2.64 Million - $3.63 Million	-39,274 Reduced 1.25%	3,109,832 $270 Million
Q1 2021 May 17, 2021	SELL	$72.16 - $117.4 $26.1 Million - $42.5 Million	-361,864 Reduced 10.31%	3,149,106 $260 Million
Q4 2020 Feb 16, 2021	BUY	$38.09 - $100.95 $134 Million - $354 Million	3,510,970 New	3,510,970 $319 Million

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $163M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Fate Therapeutics Inc Transaction History